Company profile RAPT

RAPT Therapeutics Inc
rapt therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. utilizing its proprietary discovery and development engine, the company is developing highly selective small molecules designed to mo...dulate the critical immune drivers underlying these diseases. rapt has discovered and advanced two unique drug candidates, flx475 and rpt193, each targeting c-c motif chemokine receptor 4 (ccr4), for the treatment of cancer and inflammation, respectively. the company is also pursuing a range of targets that are in the discovery stage of development. Show More
Quarter analysis & expected interest

There is not enough data for RAPT Therapeutics -stock -company to provide analysis

Correlation between past revenue and RAPT Therapeutics -stock -company search interest

There is not enough data for RAPT Therapeutics -stock -company to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for RAPT Therapeutics -stock -company to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for RAPT Therapeutics login to provide analysis

Correlation between past revenue and RAPT Therapeutics login search interest

There is not enough data for RAPT Therapeutics login to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for RAPT Therapeutics login to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 13:21:48.

After 39 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 52 days it will total up to 0.0.
RAPT Therapeutics news expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).

YearQ1Q2Q3Q4
201967
0
-100.0% QoQ
75
inf% QoQ
127
69.3% QoQ
2020 33
-50.7% YoY -74.0% QoQ
51
inf% YoY 54.5% QoQ
161
114.7% YoY 215.7% QoQ
114
-10.2% YoY -29.2% QoQ
2021 148
348.5% YoY 29.8% QoQ
316
519.6% YoY 113.5% QoQ
236
46.6% YoY -25.3% QoQ
70
-38.6% YoY -70.3% QoQ
2022 43
-70.9% YoY -38.6% QoQ
195
-38.3% YoY 353.5% QoQ
75
-68.2% YoY -61.5% QoQ
281
301.4% YoY 274.7% QoQ
2023 269
525.6% YoY -4.3% QoQ
59
-69.7% YoY -78.1% QoQ
0
-100.0% YoY -100.0% QoQ
32
-88.6% YoY inf% QoQ
2024 0
-100.0% YoY -100.0% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and RAPT Therapeutics news search interestLast update: February 09 2024 13:21:47.
Correlation coefficient between keyword and revenue is -0.14
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 13:21:49.

The average 5 years interest of RAPT Therapeutics news was 9.01 per week.
The last year interest of RAPT Therapeutics news compared to the last 5 years has changed by -61.6%.
This is something to be checked.
The last year interest is quite lower compared to 5 years ago. It has decreased by -40.45%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 13:21:56.

After 39 days of this quarter the interest is at 44.0. Based on that we can calculate that during remaining 52 days it will total up to 103.0.
That appears to be equal to previous quarter and same quarter last year.

YearQ1Q2Q3Q4
201929
59
103.4% QoQ
33
-44.1% QoQ
52
57.6% QoQ
2020 124
327.6% YoY 138.5% QoQ
197
233.9% YoY 58.9% QoQ
65
97.0% YoY -67.0% QoQ
229
340.4% YoY 252.3% QoQ
2021 133
7.3% YoY -41.9% QoQ
58
-70.6% YoY -56.4% QoQ
240
269.2% YoY 313.8% QoQ
55
-76.0% YoY -77.1% QoQ
2022 192
44.4% YoY 249.1% QoQ
102
75.9% YoY -46.9% QoQ
127
-47.1% YoY 24.5% QoQ
97
76.4% YoY -23.6% QoQ
2023 120
-37.5% YoY 23.7% QoQ
23
-77.5% YoY -80.8% QoQ
116
-8.7% YoY 404.3% QoQ
124
27.8% YoY 6.9% QoQ
2024 44
-63.3% YoY -64.5% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and RPT193 search interestLast update: February 09 2024 13:21:54.
Correlation coefficient between keyword and revenue is 0.34
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 13:21:58.

The average 5 years interest of RPT193 was 8.5 per week.
The last year interest of RPT193 compared to the last 5 years has changed by -18.82%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 41.68%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 13:22:03.

After 39 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 52 days it will total up to 0.0.
FLX475 expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).

YearQ1Q2Q3Q4
201937
75
102.7% QoQ
30
-60.0% QoQ
83
176.7% QoQ
2020 35
-5.4% YoY -57.8% QoQ
57
-24.0% YoY 62.9% QoQ
47
56.7% YoY -17.5% QoQ
79
-4.8% YoY 68.1% QoQ
2021 279
697.1% YoY 253.2% QoQ
45
-21.1% YoY -83.9% QoQ
196
317.0% YoY 335.6% QoQ
77
-2.5% YoY -60.7% QoQ
2022 52
-81.4% YoY -32.5% QoQ
86
91.1% YoY 65.4% QoQ
38
-80.6% YoY -55.8% QoQ
75
-2.6% YoY 97.4% QoQ
2023 95
82.7% YoY 26.7% QoQ
96
11.6% YoY 1.1% QoQ
104
173.7% YoY 8.3% QoQ
117
56.0% YoY 12.5% QoQ
2024 0
-100.0% YoY -100.0% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and FLX475 search interestLast update: February 09 2024 13:22:03.
Correlation coefficient between keyword and revenue is 0.18
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 13:22:04.

The average 5 years interest of FLX475 was 6.52 per week.
The last year interest of FLX475 compared to the last 5 years has changed by 14.42%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 57.72%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for CCR4 antagonist to provide analysis

Correlation between past revenue and CCR4 antagonist search interest

There is not enough data for CCR4 antagonist to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for CCR4 antagonist to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for cancer treatment RAPT Therapeutics to provide analysis

Correlation between past revenue and cancer treatment RAPT Therapeutics search interest

There is not enough data for cancer treatment RAPT Therapeutics to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for cancer treatment RAPT Therapeutics to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for inflammatory diseases therapy to provide analysis

Correlation between past revenue and inflammatory diseases therapy search interest

There is not enough data for inflammatory diseases therapy to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for inflammatory diseases therapy to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for RAPT Therapeutics pipeline to provide analysis

Correlation between past revenue and RAPT Therapeutics pipeline search interest

There is not enough data for RAPT Therapeutics pipeline to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for RAPT Therapeutics pipeline to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for RAPT
Earnings date: 2024-03-07 After close
Company name: RAPT Therapeutics Inc
Sector: Professional, Scientific, and Technical Services
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-02-25T07:18:13.478Z

Reuters
GSK to buy Canada's 35Pharma for $950 million

2026-02-11T20:51:00-05:00

PR Newswire
Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders?

2026-02-11T20:02:00-05:00

PR Newswire
Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders?

2026-02-06T16:29:00-05:00

PR Newswire
Halper Sadeh LLC is Investigating Whether NWE, DHIL, RAPT are Obtaining Fair Prices for its Shareholders

2026-02-02T15:30:00-05:00

PR Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger--JHG, FOLD, RAPT, and EXAS

2026-01-28T18:41:00-05:00

PR Newswire
Halper Sadeh LLC Encourages PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights

2026-01-28T14:23:00-05:00

PR Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--PEN, RAPT, NATH, and LSTA

2026-01-21T19:20:44Z

Analyst Upgrades
Barclays Downgrades RAPT Therapeutics to Equal-Weight, Announces $58 Price Target

2026-01-21T12:57:28Z

Analyst Upgrades
Leerink Partners Downgrades RAPT Therapeutics to Market Perform, Announces $58 Price Target

2026-01-21T00:40:00-05:00

PR Newswire
Halper Sadeh LLC Encourages CVGW, RAPT, CFLT Shareholders to Contact the Firm to Discuss Their Rights

2026-01-20T20:06:48Z

Analyst Upgrades
Wells Fargo Downgrades RAPT Therapeutics to Equal-Weight, Announces $58 Price Target

2026-01-20T19:44:59Z

Analyst Upgrades
LifeSci Capital Downgrades RAPT Therapeutics to Market Perform

2026-01-20T14:34:00-05:00

PR Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of RAPT Therapeutics, Inc. (NASDAQ: RAPT)

2026-01-20T19:13:41Z

GlobeNewswire
Forbion Announces Second Exit from Forbion Growth Fund III Following $2.2 Billion Acquisition of RAPT Therapeutics by GSK

2026-01-20T18:25:48Z

Analyst Upgrades
TD Cowen Downgrades RAPT Therapeutics to Hold